ClinicalTrials.gg
CompletedNCT03826901Updated Feb 24, 2025

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

A Phase 1 interventional study of delgocitinib in Atopic Dermatitis, sponsored by LEO Pharma. Completed at 16 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by LEO Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Dermatitis, Atopic by LEO Pharma — 1 open to participants now, 1 under way, 1 of them phase 3. Dermatitis, Atopic · LEO Pharma.

Enrollment
22nd of 34
46 · median 70
Started
2019
with 1 other
Phase 1
14 of 36
none open now
Registered
27th of 36
by date

Among the 36 studies in Dermatitis, Atopic by LEO Pharma, this one is the 22nd largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2019, is one of 14 in phase 1, and was the 27th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 36 studies in Dermatitis, Atopic by LEO Pharma is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Dermatitis, Atopic by LEO Pharma, or all of them as a file.
02

Study summary

This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.

Read the detailed description

A phase 1 open-label, multi-centre, single-arm trial to evaluate the safety and pharmacokinetics (including MUsT) of twice daily topical application of delgocitinib cream for 8 weeks in adults, adolescents, and children with moderate to severe atopic dermatitis

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • adults, pediatric
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria (Part 1: adults and adolescents; 12 years and above)

  • Diagnosis of atopic dermatitis (AD) as defined by the Hanifin and Rajka (1980) criteria for AD
  • Age 12 years and above at baseline
  • AD involvement of 25-50% treatable body surface area (BSA) at screening and at baseline
  • Moderate to severe AD (Validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of at least 3) at screening and at baseline

Key Inclusion criteria (Part 2: children; 2-11 years)

  • Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD
  • Age 2-11 years at baseline
  • History of AD for at least 3 months (children aged 2-5 years), and at least 12 months (children aged 6-11 years)
  • AD involvement of ≥35% treatable BSA at screening and at baseline
  • Moderate to severe AD (vIGA-AD score of at least 3) at screening and at baseline

Key Exclusion criteria (Part 1 and 2: subjects aged 2 years and above)

  • Active dermatologic conditions that may interfere with the diagnosis of AD
  • Use of tanning beds or phototherapy within 4 weeks prior to baseline
  • Systemic treatment with /modulating drugs or within 4 weeks prior to baseline or 3 or more bleach baths any week within 4 weeks prior to baseline
  • Treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), topical phosphodiesterase-4, or oral antibiotics within 1 week prior to baseline
  • infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to baseline
  • Any disorder, which is not stable, and in the investigator's opinion could affect the safety of the subject, influence the results of the trial or impede the subject's ability to complete the trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Part 1: adults and adolescents (12 years and above)

    Delgocitinib cream (dosage: A mg/g).

    Drug: delgocitinib

  • Experimental
    Part 2: children (2-11 years)

    Delgocitinib cream (dosage: B mg/g).

    Drug: delgocitinib

Interventions

  • Cream for topical application

    Also known as: LEO 124249

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Number of AEs and number of subjects with AEs

    Time frame: Week 0 to Week 8

Secondary outcomes

  1. PK parameter - Cmax

    Cmax

    Time frame: at Day 8

  2. PK parameter - AUC

    AUC

    Time frame: at Day 8

  3. PK parameter - tmax

    tmax

    Time frame: at Day 8

07

Study locations

16 sites
  • LEO Pharma investigational site
    Birmingham, Alabama 35209, United States
  • LEO Pharma investigational site
    Phoenix, Arizona 85006, United States
  • LEO Pharma investigational site
    Fountain Valley, California 92708, United States
  • LEO Pharma investigational site
    Irvine, California 92697, United States
  • LEO Pharma investigational site
    Los Angeles, California 90027, United States
  • LEO Pharma investigational site
    Centennial, Colorado 80112, United States
  • LEO Pharma investigational site
    New Haven, Connecticut 06519, United States
  • LEO Pharma investigational site
    Indianapolis, Indiana 46250, United States
  • LEO Pharma investigational site
    Ypsilanti, Michigan 48197, United States
  • LEO Pharma investigational site
    Tulsa, Oklahoma 74136, United States
  • LEO Pharma investigational site
    Medford, Oregon 97504, United States
  • LEO Pharma investigational site
    San Antonio, Texas 78218, United States
  • LEO Pharma investigational site
    Red Deer, Alberta 46-37535, Canada
  • LEO Pharma investigational site
    Hamilton, Ontario L8S 1G5, Canada
  • LEO Pharma investigational site
    Montreal, Quebec H3T 1C5, Canada
  • LEO Pharma investigational site
    Montréal, Quebec H2K 4L5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Oct 2021, 32 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 32 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2019
First posted
Feb 1, 2019
StartActual
Feb 20, 2019
Primary completionActual
Oct 29, 2021
CompletionActual
Oct 29, 2021
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03826901
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Feb 1, 2019
Start date
Feb 20, 2019
Primary completion
Oct 29, 2021
Completion
Oct 29, 2021
Last update
Feb 24, 2025

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion